Akari Therapeutics Plc Stock News

Akari Therapeutics, Plc (NASDAQ:AKTX) was the recipient of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 15,700 shares, a drop of 74.4% from the October 31st total of 61,300 shares. Based on an average daily volume of 113,700 shares, the short-interest ratio is []

Akari Therapeutics, Plc (NASDAQ:AKTX) was the target of a large decline in short interest in November. As of November 15th, there was short interest totalling 15,700 shares, a decline of 74.4% from the October 31st total of 61,300 shares. Based on an average daily volume of 113,700 shares, the days-to-cover ratio is currently 0.1 days. []

Shares of Akari Therapeutics, Plc (NASDAQ:AKTX) passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.73 and traded as low as $1.50. Akari Therapeutics shares last traded at $1.54, with a volume of 228,235 shares. The company has a market capitalization []

Akari Therapeutics, Plc (NASDAQ:AKTX) was the target of a significant increase in short interest during the month of October. As of October 29th, there was short interest totalling 61,300 shares, an increase of 48.8% from the October 14th total of 41,200 shares. Based on an average daily volume of 108,200 shares, the days-to-cover ratio is []

NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and

NEW YORK and LONDON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and

NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and

NEW YORK and LONDON, July 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to t

NEW YORK and LONDON, June 29, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and

The FDA has granted Fast Track designation to Akari Therapeutics Plc's (NASDAQ: AKTX) nomacopan to treat patients with moderate and severe Bullous Pemphigoid (BP). Nomacopan has also been granted

NEW YORK and LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and

FDA investigational new drug application (IND) now open

Study of porcine model of blast injury and haemorrhagic shock underway with USAISR as part of the development of a clinical path for the use of nomacopan to treat trauma Study of porcine model of blas

Akari Therapeutics Plc (NASDAQ: AKTX) announces new data from PASylated nomacopan published in the journal CELLS. In a non-infectious allergic uveitis animal model, PAS-nomacopan reduced VEGF by m

NEW YORK and LONDON, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and